STORY SUMMARY

A precision T-cell therapy stalls treatment-resistant cancers in clinical trial

Experimental drug invika halts progression of refractory tumors by selectively stimulating tumor-fighting T cells.

This is a brief summary of reporting from NIH News Releases. Read the original for the full article and context.

Read original reporting ↗

More from NIH News Releases · Latest headlines